279 related articles for article (PubMed ID: 30242021)
1. A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.
Lizotte PH; Hong RL; Luster TA; Cavanaugh ME; Taus LJ; Wang S; Dhaneshwar A; Mayman N; Yang A; Kulkarni M; Badalucco L; Fitzpatrick E; Kao HF; Kuraguchi M; Bittinger M; Kirschmeier PT; Gray NS; Barbie DA; Jänne PA
Cancer Immunol Res; 2018 Dec; 6(12):1511-1523. PubMed ID: 30242021
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial approaches targeting the EGFR family and c-Met in SCCHN.
Wang D; Lu Y; Nannapaneni S; Griffith CC; Steuer C; Qian G; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; He X; Chen ZG; Saba NF
Oral Oncol; 2021 Jan; 112():105074. PubMed ID: 33142224
[TBL] [Abstract][Full Text] [Related]
4. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
5. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Agulnik M
Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
7. Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID.
Gee S; Nelson N; Bornot A; Carter N; Cuomo ME; Dovedi SJ; Smith PD; Gianni D; Baker DJ
SLAS Discov; 2020 Jul; 25(6):581-590. PubMed ID: 32375580
[TBL] [Abstract][Full Text] [Related]
8. Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis.
Kao HF; Huang HC; Liao BC; Hong RL
BMC Cancer; 2022 Nov; 22(1):1228. PubMed ID: 36443704
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
[TBL] [Abstract][Full Text] [Related]
12. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
13. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
[TBL] [Abstract][Full Text] [Related]
14. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
[TBL] [Abstract][Full Text] [Related]
15. A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Box C; Mendiola M; Gowan S; Box GM; Valenti M; Brandon Ade H; Al-Lazikani B; Rogers SJ; Wilkins A; Harrington KJ; Eccles SA
Eur J Cancer; 2013 Jul; 49(11):2512-21. PubMed ID: 23582742
[TBL] [Abstract][Full Text] [Related]
16. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
17. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
19. Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
Kao HF; Liao BC; Huang YL; Huang HC; Chen CN; Chen TC; Hong YJ; Chan CY; Chia JS; Hong RL
Clin Cancer Res; 2022 Apr; 28(8):1560-1571. PubMed ID: 35046059
[TBL] [Abstract][Full Text] [Related]
20. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]